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its highly cross-linked structure also presents a major
barrier to cell movement (Dvorak et al., 1995; Senger,
1996). To invade fibrin networks, migrating endothelial
cells are believed to mobilize proteolytic enzymes whose
activities are limited to pericellular compartments (Pep-
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Ann Arbor, Michigan 48109 To date, the ability of endothelial cells to mediate
fibrinolytic activity has been largely attributed to a triad
of serine proteinases, which includes tissue-type plas-
Summary minogen activator (tPA), urokinase-type plasminogen
activator (uPA), and plasminogen (Montesano et al.,
During angiogenesis, endothelial cells penetrate fibrin 1990; Carmeliet et al., 1994; Bugge et al., 1995, 1996;
barriers via undefined proteolytic mechanisms. We Ploplis et al., 1995; Koolwijk et al., 1996; Sabapathy et
demonstrate that the fibrinolytic plasminogen activa- al., 1997). While neither tPA nor uPA degrades fibrin
tor (PA)-plasminogen system is not required for this directly, both enzymes catalyze the processing of plas-
process, since tissues isolated from PA- or plasmino- minogen to the powerful fibrinolysin, plasmin. Consis-
gen-deficient mice successfully neovascularize fibrin tent with the fibrinolytic potential of the plasminogen
gels. By contrast, neovessel formation, in vitro and activator (PA) system, numerous cell types (including
in vivo, is dependent on fibrinolytic, endothelial cell- keratinocytes, smooth muscle cells, and inflammatory
derived matrix metalloproteinases (MMP). MMPs di- cells) display major defects in their ability to invade or
rectly regulate this process as invasion-incompetent degrade fibrin deposits in PA- or plasminogen-deficient
cells penetrate fibrin barriers when transfected with states in vivo (Carmeliet et al., 1994, 1997a, 1997b, 1998;
the most potent fibrinolytic metalloproteinase identi- Bugge et al., 1996a, 1996b; Romer et al., 1996). However,
fied in endothelium, membrane type-1 MMP (MT1- in these same animals, gross alterations in either the
MMP). Membrane display of MT1-MMP is required, as neovascularization of fibrin-rich tissues or the reendo-
invasion-incompetent cells expressing a fibrinolyti- thelialization of damaged vessel walls have not been
cally active, transmembrane-deleted form of MT1- noted (Bugge et al., 1996a, 1996b, 1997; Romer et al.,
MMP remain noninvasive. These observations identify
1996; Carmeliet et al., 1997b, 1998). Consequently, in-
a PA-independent fibrinolytic pathway wherein teth-
creased interest has focused on the possibility that en-ered MMPs function as pericellular fibrinolysins during
dothelial cells do not rely on the PA-plasminogen systemthe neovascularization process.
to breach fibrin barriers in vivo and that alternate, but
uncharacterized, fibrinolytic proteinases exist (Bugge et
al., 1996b, 1997).Introduction
We now report the identification of a PA- and plasmin-
ogen-independent proteolytic system that allows endo-Proangiogenic signals associated with wound healing,
thelial cells to invade and neovascularize fibrin-richinflammation, or tumor growth induce rapid increases
tissues both in vitro and in vivo. Unexpectedly, the endo-in vascular permeability in surrounding blood vessels
thelial cell-associated fibrinolytic activity associated(Dvorak et al., 1986; Eitzman et al., 1996; Senger, 1996;
with invasive activity is not mediated by serine, cysteine,Risau, 1997). In turn, the blood-clotting protein, fibrino-
or aspartate proteinases, but instead by an enzyme be-gen, leaks out of the vascular bed where it is polymerized
longing to the matrix metalloproteinase (MMP) gene fam-and cross-linked enzymatically into a dense fibrin gel
(Dvorak et al., 1995; Senger, 1996). This deposited fibrin ily. Further studies demonstrate that membrane type-1
network then serves as a temporary scaffolding, or pro- matrix metalloproteinase (MT1-MMP), a member of a new
visional matrix, for ingressing endothelial cells that sub- subclass of membrane-anchored MMPs (Basbaum and
sequently engage morphogenetic programs to generate Werb, 1996; Werb, 1997), can degrade cross-linked fi-
patent vessels (Gailit and Clark, 1994; Folkman and brin gels and directly mediate invasive as well as tubulo-
D'Amore, 1996; Risau, 1997). While the fibrin matrix genic programs. Together, these studies identify matrix
serves as a structural support for neovascularization, metalloproteinases as a required, and previously unsus-
pected, component of the PA- and plasminogen-inde-
pendent fibrinolytic program engaged by endothelial³ To whom correspondence should be addressed (e-mail: sjweiss@
cells during angiogenic processes.umich.edu).
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Figure 1. Neovessel Formation by Fibrin-Embedded Murine Explants
(A and B) Rat tissue explants were embedded in a transparent fibrin gel and examined by phase contrast microscopy after 1 day (A) or 12
days (B) in culture at which time an anastomosing network of neovessels had formed (3120).
(C and D) Transverse light sections of 12-day-old cultures stained with endothelial cell-specific, anti-RECA-1 monoclonal antibody (C) or anti-
a-smooth muscle cell actin monoclonal antibody (D). Arrows indicate RECA-1-positive vessels (C) and a-smooth muscle cell actin-positive
fibroblasts/myofibroblasts (D) (3300). Weak staining of endothelial cells for a-smooth muscle cell actin was observed occasionally. Transmission
electron micrographs of 12-day-old neovessels depict the formation of tight junctions (E, 332,000) and a basement membrane-like subendothe-
lial matrix (F, 345,000). Arrowheads indicate tight junctions (E) or basement membrane (F).
Results endothelial-lined neovessels was formed and surrounded
by a-smooth muscle actin-positive, fibroblast-like cells
(Figures 1C and 1D). As observed in vivo (Gailit andPA-Plasminogen Deficiency Does Not Affect
Fibrin Neovascularization Clark, 1994), the endothelial cells lining the vessels ex-
pressed junctional complexes and deposited a base-To characterize the proteolytic mechanisms mobilized
during neovessel formation, an ex vivo model of neoves- ment membrane-like matrix (Figures 1E and 1F).
To determine whether the remodeling of the fibrinsel formation was developed wherein tissue explants
from normal or transgenic animals were embedded in matrix that accompanied endothelial cell invasion and
tubulogenesis was dependent on either of the PA sys-uniform fibrin gels prepared at physiologically relevant
concentrations (Figure 1A). During the first 4 days of tems or plasminogen, explants were cultured in the pres-
ence of (1) neutralizing antibodies directed against mu-culture, fibroblast-like mesenchymal cells alone migrate
into the gel (data not shown). Subsequently, patent tu- rine tPA or uPA, (2) soluble recombinant uPA receptor (to
competitively inhibit uPA binding to the uPA receptor), orbules begin to form on day 5 with peak neovasculariza-
tion occurring by day 12 where 141 6 21 tubules/explant (3) recombinant plasminogen activator inhibitor-2 (PAI-
2; an inhibitor of two-chain uPA and tPA) (Pepper et al.,were formed (mean 6 1 SD of 10 experiments; Figure
1B). At this time, an anastomosing network of patent, 1996; Yebra et al., 1996). However, regardless of whether
MMPs Act as Pericellular Fibrinolysins
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Figure 2. The PA-Plasminogen Axis in Neovessel Formation
(A and B) Rat muscle explants were cultured in fibrin gels alone (A) or with a mixture of anti-tPA (20 mg/ml), anti-uPA (5 mg/ml), soluble
recombinant uPA receptor (0.5 mg/ml), recombinant PAI-2 (20 mg/ml), and aprotinin (200 mg/ml) for 12 days (B). In the presence of these
inhibitors, the fibrinolytic activity of isolated rat endothelial cells was inhibited by 99%. No differences were detected in neovessel formation
as assessed in transverse light sections (3300).
(C±F) Neovessel formation was compared in fibrin-embedded explants isolated from wild-type or uPA2/2/tPA2/2 and cultured for 12 days in
their respective autologous sera (10% final). In transverse light sections (3400) or transmission electron micrographs (325,000) of wild-type
(C and E) or uPA2/2/tPA2/2 (D and F) explants, no differences in neovessel formation or structure were observed.
(G and H) Neovessel formation by plasminogen2/2 explants cultured in 10% autologous sera proceeded at a rate indistinguishable from
controls (G). Results are expressed in the mean number of neovessels formed 6 1 SEM (n 5 4). Neovessel structure in plasminogen2/2
explants (H) was also comparable to controls as assessed by transmission electron microscopy (325,000).
these inhibitors were added individually or in combina- at the endothelial cell±fibrin interface, tissue explants
from mice with combined deficiencies in uPA and tPAtion, neovessel formation progressed in a manner indis-
tinguishable from that observed in control explants (Fig- were embedded in fibrin gels and the angiogenic re-
sponse monitored. Wild-type mouse explants generatedures 2A and 2B).
To determine whether critical quantities of uPA or tPA fewer neovessels than rat explants (36 6 6 neovessels/
explant; n 5 5), but no significant alterations in vesselescaped inhibition in sequestered environments formed
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number, length, diameter, or ultrastructure were ob- clots (data not shown). However, nonendothelial mesen-
chymal cells (i.e., predominately fibroblasts and myofi-served when the responses of wild-type or uPA2/2/
broblasts as defined by smooth muscle cell actin stain-tPA2/2 tissues were compared directly (Figures 2C±2F).
ing; Nicosia and Tuszynski, 1994) retained the ability toOf note, neovessel lumens were clear of fibrin deposits
populate the surrounding matrix in the presence of MMPdespite the absence of a functional PA system (Figures
inhibitors (Figures 3B and 3D). When either wild-type,2C and 2F). Similar results were obtained when the fibrin
uPA2/2/tPA2/2, or plasminogen2/2 explants were substi-concentration was increased from 3 mg/ml to 6 mg/ml.
tuted for rat tissues, neovessel formation, but not fibro-While uPA and tPA act as the primary activators of
blast/myofibroblast migration, was similarly blocked byplasminogen, alternative pathways exist that might sup-
BB-94 or TIMP-2.port PA-independent plasmin formation (Bugge et al.,
The ability of MMP inhibitors to selectively block en-1996b). Thus, explants from plasminogen2/2 mice were
dothelial cell invasion suggested that MMPs regulatealso examined for their ability to neovascularize fibrin
fibrin-invasive activity in a cell-specific manner. To con-gels. Consistent with the results obtained with uPA2/2/
firm this possibility, explant-derived fibroblasts and my-tPA2/2 tissues, the angiogenic response was unaffected
ofibroblasts, or endothelial cells were isolated and reem-by the absence of plasminogen (Figures 2G and 2H).
bedded separately in fibrin gels. In the presence of MMPSimilarly, potent inhibitors of plasmin-mediated fibrinol-
inhibitors, explant-derived fibroblasts and myofibro-ysis (i.e., aprotinin or e-aminocaproic acid) (Pepper et
blasts underwent a neuritic-like change in cell shapeal., 1996) did not affect neovessel formation by either
but continued to express an invasive phenotype (Figurewild-type, uPA2/2/tPA2/2, or plasminogen2/2 explants
3F). However, under the same conditions, the addition(data not shown). Thus, neither uPA, tPA, nor plasmino-
of MMP inhibitors completely blocked the invasion ofgen played a required role in the neovascularization
the isolated endothelial cells into the surrounding fibrinprocess.
gel (Figures 3G and 3H). Thus, while the ability of fibro-
blasts/myofibroblasts to mount a PA-, plasminogen-,
or MMP-independent migratory response is consistentMatrix Metalloproteinases Regulate Neovessel
with a nonproteolytic, mechanical process (Brown et al.,Formation In Vitro and In Vivo
1993), endothelial cell invasion was dependent on MMPTo identify alternate proteinases that mediated fibrin-
activity.invasive or tubulogenic activity, wild-type explants were
Because ex vivo studies supported a primarily role forfirst cultured in the presence of broad-spectrum inhibi-
MMPs rather than the PA-plasminogen axis in regulatingtors directed against serine proteinases (soybean tryp-
endothelial cell invasion and tubulogenesis, a require-sin inhibitor and a1 proteinase inhibitor), cysteine pro-
ment for MMPs in the neovascularization of fibrin matri-teinases (E-64), or aspartate proteinases (pepstatin A)
ces was tested in vivo. Thus, fibrin gels or plasma clots(Reddy et al., 1995). However, none of these inhibitors
were mixed with a cocktail of proangiogenic factors (seealone or in combination affected neovessel formation
Experimental Procedures) in the absence or presence(data not shown).
of TIMP-2, sealed in perforated plastic chambers andEndothelial cells, as well as other mesenchymal cell
implanted subcutaneously in wild-type mice. After a 10populations, can also synthesize a variety of secreted
day incubation period, the chambers were recovered andand membrane-anchored proteinases belonging to the
the angiogenic response assessed in tissue sections.MMP gene family (Basbaum and Werb, 1996; Werb,
Macroscopically, both the TIMP-free and TIMP-con-1997). Like the PA-plasminogen axis, MMPs have also
taining chambers were surrounded by large numbers ofbeen implicated in matrix remodeling events, but neither
neocapillaries in situ. However, when the chambers were
endothelial cells nor any other cell type have been shown
freed of surrounding connective tissues and opened,
to use this class of proteinases to penetrate fibrin barri-
striking differences in the vascularization of the im-
ers. To determine whether MMPs were expressed during
planted fibrin gels were noted (Figure 4). As shown at
the neovascularization of fibrin gels, total RNA was ex- both the light and TEM levels, while TIMP-free chambers
tracted from either freshly isolated or 6- to 12-day-old were infiltrated with large numbers of neovessels, no
fibrin-embedded explants and assessed by RT-PCR. blood vessels were identified in the presence of TIMP-2
While gelatinase A/MMP-2 and membrane-type matrix in either fibrin implants (Figures 4C±4F) or plasma clots
metalloproteinase-1 (MT1-MMP) were detected in both (data not shown). As observed in the in vitro explant
control and neovascularizing explants, tissues actively model, nonendothelial mesenchymal cells retained the
engaged in the angiogenic response additionally ex- ability to infiltrate the fibrin gels in the presence of the
pressed gelatinase B/MMP-9, stromelysin-1, stromely- MMP inhibitor (Figures 4D and 4F). Taken together,
sin-2, stromelysin-3, matrilysin, and metalloelastase. these data support the contention that MMPs play a
Given the active regulation of a complex MMP pro- required role in the neovascularization of fibrin-rich tis-
gram during the angiogenic response, we sought to de- sues in vitro as well as in vivo.
termine whether MMP inhibitors would alter neocapillary
development in the explant model. As shown in Figure 3,
tissue inhibitor of metalloproteinases-2 (TIMP-2) or the Endothelial Cell MMPs Express PA- and
hydroxyamate-based synthetic inhibitor, BB-94 (Bas- Plasminogen-Independent
baum and Werb, 1996; Botos et al., 1996), completely Fibrinolytic Activity
blocked neovessel formation in the course of a 12 day If endothelial cells use MMPs as direct-acting fibrinoly-
sins, (1) the onset of invasive activity should coincideculture period in fibrin gels (Figures 3A±3D) or in plasma
MMPs Act as Pericellular Fibrinolysins
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Figure 3. Effect of MMP Inhibitors on Neovessel Formation In Vitro
(A±D) Rat tissue explants were cultured in fibrin gels for 12 days in the absence (A and C) or presence of 20 mg/ml TIMP-2 (B and D). Phase
contrast microscopy (3120) demonstrated that neovessel formation was completely blocked by the MMP inhibitor (A versus B). Transverse
light sections (3300) confirmed the presence of patent tubules in control, but not TIMP-2-treated cultures (C versus D). In the presence of
TIMP-2 or BB-94, infiltrating populations of RECA-1-negative/a-smooth muscle actin-positive fibroblasts/myofibroblasts were detected (data
not shown).
(E±H) Isolated, rat explant-derived fibroblasts/myofibroblasts (E and F) or rat endothelial cells (G and H) were embedded in fibrin gel in the
absence (E and G) or presence of 5 mM BB-94 (F and H) and examined by phase contrast microscopy (3100). Migration from fibrin gel implants
(marked by asterisks) into the surrounding fibrin matrix is shown after a 7 day incubation period. While the MMP inhibitor altered the shape
of the migrating fibroblasts/myofibroblasts, motility was preserved (E and F). In contrast, endothelial cell outgrowth from implants (marked
by asterisks) was inhibited completely by BB-94 (G and H).
with the MMP-dependent degradation of the fibrin sub- of three experiments). However, when endothelial cells
were stimulated in the presence of either BB-94 or TIMP-stratum and (2) one or more of the subset of MMPs
expressed by the invading endothelial cells should dis- 2, endothelial cell-mediated fibrinolysis was reduced to
resting levels (i.e., 98% 6 3% and 94% 6 12% inhibitionplay fibrinolytic activity under cell-free conditions. In the
course of a 12 day incubation, growth factor±stimulated of fibrinolysis; n 5 3) and endothelial cell invasion of the
underlying fibrin gel was inhibited completely (Figuresendothelial cells invaded an underlying [125I]-labeled fi-
brin gel (Figures 5A±5D) and increased the solubilization 5E and 5F). Invasion was similarly inhibited by BB-94 or
TIMP-2 when endothelial cells were stimulated to invadeof the substratum by 3-fold in the presence of aprotinin
(i.e., from 642 6 195 to 1596 6 468 cpm; mean 6 1 SEM fibrin gels cultured in the absence of aprotinin (Figures
Cell
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Figure 4. Effect of MMP Inhibition on Neo-
vascularization In Vivo
(A±F) Fibrin gels containing a cocktail of angi-
ogenic factors (see Experimental Proce-
dures) with or without TIMP-2 were sealed in
perforated plastic chambers and implanted
subcutaneously in wild-type mice for 10 days.
Chambers were removed and processed for
microscopy. Vascularized implants neoves-
sels enter the perforated chambers in the
control implants (A, 330) and displayed nor-
mal ultrastructure by light (C, 3320) or elec-
tron microscopy (E, 37350). No blood vessels
were detected in TIMP-2-containing fibrin
gels (B, D, and F). In the presence of TIMP-2,
nonendothelial mesenchymal cells retained
invasive activity (D and F). Results are repre-
sentative of four independent experiments.
Arrowheads indicate the position of neoves-
sels in (A).
5G and 5H). While MMP inhibitors may have affected analysis of fibrin(ogen) following incubation with soluble
MT1-MMP, the most potent fibrinolytic MMP identified,invasion by modifying cell motility or proliferation (Cor-
coran and Stetler-Stevenson, 1995; Pilcher et al., 1997), demonstrated that whereas the Aa and Bb chains of
fibrinogen were sensitive to proteolytic attack, a-fibrinneither BB-94 nor TIMP-2 inhibited endothelial cell mi-
gration across fibrin-coated surfaces (i.e., control cells and the high molecular weight a-polymers were prefer-
entially degraded in the cross-linked gels (Figure 6C).stimulated with angiogenic factors migrated 1.1 6 0.1
mm in the absence of inhibitors and 1.4 6 0.1 and 1.1 6 Qualitatively similar results were obtained with stromely-
sin-1, collagenase-1, or gelatinase A (data not shown).0.1 mm in the presence of BB-94 or TIMP-2, respectively;
n 5 3, mean 6 1 SD) or endothelial cell proliferation in
the presence of angiogenic factors (i.e., after a 3 day MT1-MMP Regulates Fibrin-Invasive Activity
and Supports Tubulogenesisincubation, endothelial cell numbers increased from
1.0 3 106 cells to 7.5 6 1.4 3 106, 7.0 6 1.0 3 106, and Given that stromelysin-1 and MT1-MMP expressed the
strongest fibrinolytic activity under cell-free conditions,9.1 6 0.2 3 106 when cultured alone, with BB-94, or
TIMP-2, respectively; n 5 3, mean 6 1 SD). the ability of each of the enzymes to regulate cellular
invasion through fibrin matrices was examined. TakingCoincident with the invasive process, isolated endo-
thelial cells expressed a limited subset of the MMPs advantage of the recent generation of stromelysin-12/2
mice (Mudgett et al., 1998), tissue explants derived fromdetected in the more complex ex vivo model, which
included collagenase-1, stromelysin-1, MT1-MMP, and these animals were embedded in fibrin gels and neoves-
sel formation monitored. Significantly, stromelysin-12/2gelatinase A/MMP-2 (Figure 6A). To determine whether
these enzymes exhibit fibrinolytic activity, collagenase- explants initiated an angiogenic response equivalent to
stromelysin-11/1 control explants when assessed quan-1, stromelysin-1, gelatinase A/MMP-2, or a soluble,
transmembrane-deletion mutant of MT1-MMP (Pei and titatively or by morphologic criteria (Figure 7A).
As stromelysin-1 was not required for neovessel for-Weiss, 1996) were incubated with [125I]-labeled, cross-
linked fibrin gels and solubilization quantified. Under mation, we next sought to determine if MT1-MMP could
play a direct role in pericellular fibrinolysis by endowingcell-free conditions, each of the MMPs solubilized the
fibrin gels via a process that could be completely an invasion-null cell with invasive or tubulogenic proper-
ties via de novo expression of MT1-MMP. Thus, controlblocked by BB-94 or TIMP-2 (Figure 6B). SDS-PAGE
MMPs Act as Pericellular Fibrinolysins
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Figure 5. Effect of MMP Inhibitors on the Fibrin-Invasive Activity of Isolated Endothelial Cells
(A and B) Human endothelial cells were cultured atop fibrin gels for 12 days with aprotinin in the absence (A) or presence of angiogenic factors
(B) and examined by phase contrast microscopy (3100). Sprouts of invading endothelial cells are formed below the plane of focus of the
monolayer in stimulated cultures only (B).
(C±H) Transverse light sections (3200) of unstimulated monolayers (C) or cultures stimulated with growth factors in either the absence or
presence of BB-94 (D and E, respectively) or TIMP-2 (F). Endothelial cell cultures stimulated with growth factors in the absence of aprotinin
(G) similarly displayed invasive activity, which was blocked completely by TIMP-2 (H). Double-headed arrow indicates the position of the
underlying gel in (C) while arrowheads highlight invading endothelial cells in (D) and (G). Results are representative of five or more experiments.
The mean distances migrated in (C) and (H) are 35.3 6 9.7 mm and 37.8 6 4.1 mm (mean 6 1SEM, n 5 5). In the presence of MMP inhibitors,
mean invasion was 0.0 6 0.0 mm.
or MT1-MMP stable transfectants were seeded atop (Sato et al., 1994; Butler et al., 1998), the MCDK clones
used in these studies do not express gelatinase A/MMP-2fibrin gels and stimulated with the motogen scatter fac-
tor in order to elicit a motile phenotype. As shown in and invasion proceeded normally in the presence of
gelatinase A±depleted serum (Figure 7E).Figure 7B, control MDCK cells were unable to invade
the fibrin gels following a 6 day incubation period. In As MT1-MMP contains both transmembrane and cy-
tosolic domains that do not play a direct role in control-marked contrast, MT1-MMP transfectants invaded the
underlying fibrin matrix and underwent a tubulogenic ling proteolytic activity (Pei and Weiss, 1996; Ohuchi et
al., 1997), the ability of wild-type MT1-MMP to regulateresponse reminiscent of that observed with endothelial
cells (Figure 7C). Furthermore, the invasive/tubulogenic fibrin-invasive activity was directly compared to mutant
forms of the MMP in which either the cytosolic domainresponse obtained with MT1-MMP-transfected cells
was blocked completely by either BB-94 (Figure 7D) or (MT1-MMP Dcyt) or transmembrane domain was de-
leted (MT1-MMP DTM). Similarly, MT1-MMP Dcyt ex-TIMP-2 (data not shown). While MT1-MMP-transfected
cells process progelatinase A/MMP-2 to its active form pressed an invasive phenotype indistinguishable from
Cell
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Figure 6. MMP Expression in Endothelial
Cells and Fibrinolytic Activity
(A) Northern blot analysis of MMP expression
in human endothelial cells after a 3 day incu-
bation with vascular endothelial growth fac-
tor, TGFa, hepatocyte growth factor, endo-
thelial cell growth supplement, and heparin.
(B) Fibrinolytic activity of collagenase-1, stro-
melysin-1, gelatinase A, or a soluble MT1-
MMP transmembrane deletion mutant in the
absence or presence of BB-94 (values ob-
tained with the inhibitor are the bars shown to
the right in each pair). The clear and stippled
portion of each bar represents the number of
counts recovered in the media or urea ex-
tract, respectively. Results are expressed as
the mean 6 1 SEM cpm released from [125I]-
fibrin-labeled gels (n 5 3).
(C) SDS-PAGE analysis of fibrinogen or fibrin
(20 mg each) after an 18 hr incubation alone
or with soluble MT1-MMP (2.5 pM) in the ab-
sence or presence of TIMP-2 (1 mg). Aa, Bb,
and g chains of fibrinogen and the a polymer,
gg, a, and b chains of fibrin are indicated to
the left of each gel.
the full-length enzyme (Figure 7F). However, despite the 1996a, 1996b; Romer et al., 1996) and extracellular ma-
trix components (Chen and Strickland, 1997) as well asfact that MT1-MMP DTM-transfected cells secrete large
amounts of the fully active enzyme extracellularly (Pei processes MMP zymogens to active forms (Carmeliet et
al., 1997a, 1998). Consequently, this proteolytic systemand Weiss, 1996), the soluble enzyme was unable to
direct the invasive phenotype under conditions permis- had been posited to play an indispensable role in regu-
lating fibrin-invasive activity. However, our ex vivo data,sive for either of the membrane-anchored forms of the
proteinase (Figure 7G). Thus, the ability of MT1-MMP to coupled with in vivo observations made in PA2/2 or
plasminogen2/2 mice (Bugge et al., 1996a, 1996b, 1997;direct invasive activity was critically dependent on its
localization to the cell surface. Romer et al., 1996) and plasminogen-deficient humans
(Schuster et al., 1997), all support the existence of an
alternate fibrinolytic program critical to the angiogenicDiscussion
process.
Following screening with class-specific antiprotein-The deposition of a fibrin-rich matrix is tightly linked to
the initiation and propagation of angiogenic responses ases, the ability of endothelial cells to invade fibrin gels
was found to be dependent solely on the expressionin most, if not all, postdevelopmental states (Dvorak et
al., 1995; Senger, 1996). Nonetheless, the proteolytic of MMP activity in vitro as well as in vivo. Invading
endothelial cells were subsequently found to express aprocesses mobilized during neovessel formation have
remained the subject of uncertainty (Bugge et al., 1996b, number of secreted MMPs, but the cells also synthe-
sized MT1-MMP, a member of a new subclass of mem-1997; Pepper et al., 1996; Romer et al., 1996). In order for
the fibrin matrix to serve as a scaffolding for ingressing brane-anchored MMPs (Werb, 1997). Until recently, the
primary function assigned to MT1-MMP was its abilityblood vessels, invading endothelial cells should restrict
fibrinolytic activity to the pericellular milieu so that the to process the gelatinase A/MMP-2 zymogen to a series
of enzymatically active proteinases (Sato et al., 1994;bulk of the fibrin matrix is retained as a structural sup-
port. At the cell surface, PAs not only may regulate Butler et al., 1998). Because MMP-2 has been linked
indirectly to angiogenic states and can bind to cell sur-adhesion, migration, and gene expression (Chapman,
1997) but also catalyze the formation of plasmin. In turn, faces via the avb3 integrin (Brooks et al., 1996, 1998), we
initially considered its role as a potential cell-associatedplasmin efficiently degrades fibrin (Bugge et al., 1995,
MMPs Act as Pericellular Fibrinolysins
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Figure 7. Regulation of Neovessel Formation
and Fibrin-Invasive Activity by Stromelysin-1
and MT1-MMP
(A) Neovessel formation by stromelysin-12/2
or stromelysin-11/1 explants as a function of
time. Results are expressed as the mean 6
1 SEM of ten experiments with no discernible
morphologic differences observed between
control or null animals as shown in transverse
light sections (3150).
(B±G) MDCK cells transfected with control
vector did not invade fibrin gels during a 4
day incubation (B), but cells overexpressing
MT1-MMP invaded the underlying fibrin and
generated tubules (C) via a BB-94-sensitive
process (D). Depleting the sera of gelatinase
A/MMP-2 did not alter the invasive phenotype
(E). MDCK cells overexpressing MT1-MMP
Dcyt, but not MT1-MMP DTM, retained fibrin-
invasive activity (F and G, respectively). The
double-headed arrow in (B) marks the posi-
tion of the underlying fibrin gel while the
arrows in (C), (E), and (F) indicate cells invad-
ing the fibrin gel. Results are representative
of three or more experiments. The mean dis-
tances migrated in (C), (E), and (F) are 104.3 6
10.9 mm, 120.1 6 12.5 mm, and 120.0 6 14.9
mm, respectively (mean 6 1 SEM; n 5 3). In
(B), (D), and (G), mean distances migrated
were all 0.0 6 0.0 mm.
fibrinolysin. However, gelatinase A/MMP-2 did not ex- MT1-MMP-specific inhibitors have been developed, we
demonstrated that cells incapable of penetrating fibrinhibit efficient fibrinolytic activity under cell-free condi-
tions nor did it play a required role in regulating fibrin- matrices need only express MT1-MMP to acquire inva-
sive as well as tubulogenic activity. The importance ofinvasive activity. Significantly, all of these results are
consistent with reports that MMP-22/2 mice develop displaying the metalloproteinase on the cell surface was
underlined by the fact that cells overexpressing solublenormally and can successfully neovascularize fibrin-rich
wound sites in vivo (Itoh et al., 1997, 1998). MT1-MMP lost all invasive activity. A recent report has
suggested that the cytosolic domain of MT1-MMP mayWhile a MT1-MMP´gelatinase A/MMP2 couple was
not a required participant in fibrin-invasive activity, re- affect the ability of the host cell to focus the enzyme to
invasive fronts (Nakahara et al., 1997), but an absolutecent studies have demonstrated that MT1-MMP can
directly cleave extracellular matrix components (Pei and requirement for the 20-amino acid tail could not be es-
tablished in our system. As such, anchoring the activeWeiss, 1996; Ohuchi et al., 1997). Given that pericellular
proteolysis is most efficiently catalyzed by membrane- enzyme to the cell surface was the sole determinant
needed to transfer fibrin-invasive activity to a null cellassociated enzymes (Basbaum and Werb, 1996; Werb,
1997), we considered the possibility that MT1-MMP population. Nonetheless, it seems likely that the other
MMPs coexpressed in tandem with MT1-MMP play ac-might function directly as the PA/plasminogen-indepen-
dent fibrinolysin. MT1-MMP had not previously been cessory roles in the final sculpting of the mature vessel
in vivo (Hanahan, 1997).known to express fibrinolytic activity, but portions of its
catalytic domain bear strong homology to fibrinolysins Given a requirement for MMPs in vitro and in vivo
during the neovascularization of fibrin gels, the questionbelonging to a family of hemorrhagic venom metallopro-
teinases (Bode et al., 1993; Gomis-Ruth et al., 1993; Bini arises as to when and where plasmin itself participates
in fibrin turnover. First, it should be stressed that whileet al., 1996). Consistent with this structural relationship,
a soluble transmembrane-deletion mutant of MT1-MMP MT1-MMP is expressed in endothelial cells in vitro and
in vivo (Nomura et al., 1995; Zucker et al., 1995; Uenowas shown to efficiently degrade cross-linked fibrin.
Furthermore, while neither MT1-MMP-deficient mice nor et al., 1997), the enzyme is not ubiquitously expressed
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by all cell types that confront fibrin barriers in vivo. In- the proprotein convertase-dependent activation of me-
talloproteinase zymogens may have evolved as a PA/deed, the inability of keratinocytes to efficiently reepi-
thelialize fibrin-rich wounds in plasminogen2/2 animals plasminogen-independent, proteolytic-processing sys-
tem. Because the substrate specificity of membrane-correlates with their inability to express MT1-MMP in
vivo and stresses the importance of plasmin in regulat- anchored metalloproteinases extends beyond fibrin to
include a range of extracellular matrix components (Peiing invasive activity in this cell population (Bugge et al.,
1996b; Romer et al., 1996; Okada et al., 1997). Thus, a and Weiss, 1996; Ohuchi et al., 1997), these enzymes
are likely to act as critical mediators of invasive activityreliance on MMP- versus plasmin-dependent fibrinolytic
processes may be dictated by the repertoire of protein- by normal as well as neoplastic cells through multiple
structural barriers in vivo. Whether MT1-MMP uniquelyases available to the invading cell population. Second,
while all of our in vitro and in vivo studies underlined a regulates fibrin-invasive activity in vivo or whether this
function can be complimented by other membrane-typeprimary role for MMPs in endothelial cell-fibrin interac-
tions, plasmin may play important roles under other MMPs awaits the generation of deficient mice. Never-
theless, therapeutic interventions aimed at MT1-MMPpathophysiologic conditions. For example, individual
growth factors can drive distinct angiogenic programs and related membrane-anchored proteinases (Blobel,
1997; Werb, 1997) may prove useful not only in regulat-that rely on different sets of expressed integrins (Brooks
et al., 1994). Because our in vitro and in vivo models ing angiogenesis, but also the pathologic remodeling
of the extracellular matrix in tissue-destructive diseasewere all dependent on vascular endothelial growth fac-
tor (unpublished data), other angiogenic programs might states as well.
be more dependent on the PA-plasminogen axis. In-
Experimental Proceduresdeed, Koolwijk et al. (1996) have reported that isolated
endothelial cells can invade fibrin gels in vitro via a uPA-
Tissue Explant Modeldependent process. Nonetheless, it should be stressed
Abdominal muscle fragments (1.5 mm) were isolated from Fischer
that defects in the neovascularization of fibrin-rich de- rats, uPA2/2/tPA2/2, plasminogen2/2, stromelysin-12/2, or back-
posits in PA- or plasminogen-null animals have not been ground-matched wild-type mice (Carmeliet et al., 1994; Ploplis et
al., 1995; Mudgett et al., 1998) and suspended in a solution (0.9 ml)reported (Bugge et al., 1996a, 1996b, 1997; Romer et
of 3 mg/ml of PA- and plasminogen-free human fibrinogen (Calbio-al., 1996).
chem). Copolymerized gels were formed following the addition ofFinally, regardless of the importance of MMPs in regu-
15 milliunits bovine thrombin (Sigma) (Brown et al., 1993) and thelating pericellular fibrinolysis, the PA-plasminogen axis
explants cultured for 12 days at 378C in MCDB-131 (Clonetics) sup-
has been demonstrated to play the critical role in the plemented with either 20% fetal bovine serum (FBS) or 10% mouse
bulk proteolysis of fibrin-rich thrombi (Carmeliet et al., serum collected from control or null animals. Where indicated, the
fibrin gels and media were supplemented with neutralizing poly-1994; Ploplis et al., 1995; Bugge et al., 1996a). Likewise,
clonal antisera directed against murine uPA (5 mg/ml) or tPA (30 mg/following neovascularization in vivo, the remaining fibrin
ml), soluble rat uPA receptor (0.5 mg/ml; all from American Diagnos-scaffolding is normally resorbed by a plasminogen-
tica), recombinant plasminogen activator inhibitor-2 (20 mg/ml; a giftdependent process and coordinately replaced by a per-
from M. Baker, University of Wollongong, Australia), e-aminocaproic
manent collagen-based matrix (Gailit and Clark, 1994). acid (500 mg/ml; Sigma), aprotinin (200 mg/ml; Sigma), E-64 (100
If proteolysis of the provisional matrix is delayed by mM; Sigma), pepstatin A (50 mM; Sigma), recombinant TIMP-2 (20
mg/ml; Amgen), or BB-94 (5 mM; British Biotechnology).perturbing the PA-plasminogen axis, tissue reparative
processes are interrupted and fibrotic responses are
Fibrin Invasion Assaysprecipitated (Eitzman et al., 1996; Kitching et al., 1997;
Rat aorta endothelial cells or rat explant-derived fibroblasts andXiao et al., 1997). A role for MMPs in bulk fibrin clearance
myofibroblasts were isolated as described (Nicosia and Tuszynski,
has not been examined, but it is noteworthy that intra- 1994) and cultured in MCDB-131 supplemented with 20% FBS atop
vascular as well as extravascular fibrin deposits are or within fibrin gels in Transwell culture dishes (Costar). To analyze
the invasive properties of fibrin-embedded cells, rat aorta endothe-eventually cleared, albeit with altered kinetics, in PA-
lial cells or rat explant-derived fibroblasts and myofibroblasts wereor plasminogen-deficient states (Bugge et al., 1996a,
cultured atop fibrin gels, fragments excised, and then embedded1996b; Romer et al., 1996). These findings raise the
in fibrin gels as described above. Endothelial cell motility was moni-possibility that MMPs could participate secondarily in
tored by culturing cells atop fibrin gels whose surface was partially
the bulk degradation of fibrin deposits in vivo. covered with glass cloning chips. After monolayers were formed,
Membrane proteinases appear to play an increasingly the chips were removed leaving denuded areas wherein the distance
important role in the proteolytic remodeling of the ex- migrated by the advancing front of cells was measured during a 24
hr incubation.tracellular matrix (Werb, 1997). From this perspective,
Fibrin invasion in vivo was assessed by placing fibrin gels (3 mg/it is important to note that MT1-MMP is only one of
ml) or plasma clots containing a mixture of 100 ng/ml vascularfour members of the membrane-anchored MMPs (Werb,
endothelial growth factor (Genentech), 10 ng/ml TGFa (Biosource),
1997). Unlike some MMPs, which may rely on plasmin 50 ng/ml hepatocyte growth factor (Genentech), 75 mg/ml endothe-
for processing to active forms (Carmeliet et al., 1997a, lial cell growth supplement (Collaborative Research), and 100 mg/
1998), each of the MT-MMPs are encrypted with an ml heparin in the absence or presence of TIMP-2 (20 mg/ml) in
polycarbonate chambers (Dvorak et al., 1987). The chambers wereArg-X-Lys/Arg-Arg motif upstream of their respective
then sealed, one end of the chamber perforated to allow cell ingresscatalytic domains (Basbaum and Werb, 1996; Pei and
and implanted subcutaneously in wild-type mice for 10 days.Weiss, 1995, 1996; Maquoi et al., 1998). This basic tetrad
can act as a recognition sequence for intracellular pro-
MMP-Dependent Fibrinolysis
protein convertases, which then activate the cognate Human umbilical vein endothelial cells were isolated as described
MMP zymogen by removing its regulatory prodomain (Huber et al., 1991) and cultured in M-199 supplemented with 20%
human serum atop fibrin gels prepared with [125I]-labeled fibrinogen(Pei and Weiss, 1995, 1996; Maquoi et al., 1998). Thus,
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(3 3 105 cpm total; Amersham) in the absence or presence of 200 NIH grants CA71699 and HL54216, grants from the Michigan Arthritis
Center, Department of the Army (DAMD17-94-J-4322), Americanmg/ml aprotinin, 5 mM BB-94, or 20 mg/ml TIMP-2. Monolayers were
stimulated to invade with a mixture of angiogenic factors (as de- Heart Association of Michigan, and the Susan G. Komen Breast
Cancer Foundation.scribed above), which were added to the lower compartment of the
Transwell system. Solubilized fibrin contained in the media and in
a 5 M urea extract of the fibrin gel were pooled, recovered following
Received June 30, 1998; revised September 14, 1998.
centrifugation (10,000 3 g for 10 min), and quantitated by g-scintilla-
tion counting. Human endothelial cells were used in place of murine
cells for these studies given the availability of purified and recombi- References
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